PHCbi to Distribute MaxCyte ExPERT Cell Engineering Platform in Japan

MaxCyte ExPERT Platform in Japan

Image Credits: Galveston Country Daily News

Announcement

The PHC corporation, a biomedical division subsidiary of PHC Holdings Corporation, has entered an agreement with MaxCyte Inc. for the distribution of the MaxCyte ExPERT platform in Japan. In June, Singapore SciMed (Asia) Pte Ltd, a subsidiary of PHCHD, entered solo in an agreement with MaxCyte and later introduced the ExPERT platform. MaxCyte is a global cell-engineering company enabling various platform technologies for enhancing and advancing development, commercialization, and discoveries. This partnership will sign PHCbi for sales and service support for MaxCyte solutions, instruments, and consumables. This will help manufacturers and researchers to use a non-viral cell engineering platform.

MaxCyte ExPERT

MaxCyte ExPERT instrument portfolio is a future commercial and clinically proven electroporation technology for scalable and critical cell engineering. The ExPERT platform provides cell viability, smooth functionality, efficiency, and quality performance that can face the emerging challenge of cellular therapeutics and biological.

Which Agreement has Contributed to and Benefited Regional Development?

PHCbi will help and distribute the range of MaxCyte platforms that have been mentioned in the agreement, consisting of ExPERT VLx®, ExPERT ATx®, ExPERT GTs®, and ExPERT STx®. Including suitable consumables like electroporation buffers and processing assemblies. Researchers mainly use these platforms globally and have been referred to as the most preferred in 70 clinical programs and more as of Q1 2025.

The MaxCyte ExPERT platform reflects PHCbi’s ongoing efforts. The contribution to the manufacturing and development process represents a regional milestone for Japan. PHCbi’s recent LiCellMo™ is under development. This initiation is to introduce a well-optimized analyzer. Its automatic nature is based on the metabolic state of cells. Along with the MaxCte ExPERT platform, LiCellMo™ solution strengthens the PHCbi’s commitment to provide needed insights to developers and researchers, mainly in areas such as bioproduction, immunotherapy, and regenerative medicine.

Views and Statements

Director of PHC Corporation and General Manager of PHCbi, Chikara Takauo, said, “We are excited and encouraged to add MaxCyte’s ExPERT instruments to the company’s cell culture technology portfolio. The partnership, an agreement, suits our vision of ‘contributing to the evolution and progress of therapeutic modalities’. We are dedicated to discovering new solutions against the challenges of QCD (Quality, cost, and delivery) in cell and gene therapy (CGT) manufacturing process.” Further, “The additional features of MaxCyte’s ExPERT portfolio help us to support cell therapy developers and scientists by enabling them with a non-viral and strong tool for the advancement in their cell-based research and development process and indirectly elevate the acceptance of CGT."